Diabetes, hyperlipidemia, and coronary artery disease (Q33652018)

28 July 2017

1 reference

title

Diabetes, hyperlipidemia, and coronary artery disease (English)

1 reference

28 July 2017

1 reference

coronary artery disease

1 reference

Haffner SM

1

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

American Journal of Cardiology

28 July 2017

published in

1 reference

28 July 2017

volume

83

1 reference

28 July 2017

issue

9B

1 reference

28 July 2017

page(s)

17F-21F

1 reference

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Management of dyslipidemia in adults with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Management of dyslipidemia in adults with diabetes. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900213-1

10.1016/S0002-9149(99)00213-1

7 January 2021

Identifiers

DOI

1 reference

28 July 2017

1 reference